دورية أكاديمية
The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer.
| العنوان: | The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer. |
|---|---|
| المؤلفون: | Silwal-Pandit L; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway., Nord S; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway., von der Lippe Gythfeldt H; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.; Department of Oncology, Oslo University Hospital, Oslo, Norway., Møller EK; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway., Fleischer T; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway., Rødland E; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway., Krohn M; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway., Borgen E; Department of Pathology, Oslo University Hospital, Oslo, Norway., Garred Ø; Department of Pathology, Oslo University Hospital, Oslo, Norway., Olsen T; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway., Vu P; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway., Skjerven H; Department of Research, Vestre Viken Hospital Trust, Drammen, Norway., Fangberget A; Department of Radiology and Nuclear Medicine, Oslo University Hospital Radiumhospitalet, Oslo, Norway., Holmen MM; Department of Radiology and Nuclear Medicine, Oslo University Hospital Radiumhospitalet, Oslo, Norway., Schlitchting E; Department of Breast and Endocrine Surgery, Oslo University Hospital, Oslo, Norway., Wille E; Department of Oncology, Oslo University Hospital, Oslo, Norway., Nordberg Stokke M; Department of Oncology, Oslo University Hospital, Oslo, Norway., Moen Vollan HK; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.; Department of Oncology, Oslo University Hospital, Oslo, Norway., Kristensen V; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway., Langerød A; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway., Lundgren S; Department of Oncology, St. Olavs University Hospital, Trondheim, Norway.; Department of Cancer Research and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway., Wist E; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Insitute for Clinical Medicine, University of Oslo, Oslo, Norway., Naume B; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Insitute for Clinical Medicine, University of Oslo, Oslo, Norway., Lingjærde OC; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.; Department of Computer Science, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway., Børresen-Dale AL; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.; Insitute for Clinical Medicine, University of Oslo, Oslo, Norway., Engebraaten O; Department of Oncology, Oslo University Hospital, Oslo, Norway. olav.engebraten@medisin.uio.no.; Insitute for Clinical Medicine, University of Oslo, Oslo, Norway. |
| المصدر: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2017 Aug 15; Vol. 23 (16), pp. 4662-4670. Date of Electronic Publication: 2017 May 09. |
| نوع المنشور: | Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial |
| اللغة: | English |
| بيانات الدورية: | Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Denville, NJ : The Association, c1995- |
| مواضيع طبية MeSH: | Gene Expression Profiling*, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Breast Neoplasms/*drug therapy , Gene Expression Regulation, Neoplastic/*genetics, Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bevacizumab/administration & dosage ; Bevacizumab/adverse effects ; Breast Neoplasms/genetics ; Chemotherapy, Adjuvant ; Febrile Neutropenia/chemically induced ; Female ; Humans ; Hypertension/chemically induced ; Neoadjuvant Therapy ; Proteinuria/chemically induced ; Time Factors ; Treatment Outcome |
| مستخلص: | Purpose: Chemotherapy-induced alterations to gene expression are due to transcriptional reprogramming of tumor cells or subclonal adaptations to treatment. The effect on whole-transcriptome mRNA expression was investigated in a randomized phase II clinical trial to assess the effect of neoadjuvant chemotherapy with the addition of bevacizumab. Experimental Design: Tumor biopsies and whole-transcriptome mRNA profiles were obtained at three fixed time points with 66 patients in each arm. Altogether, 358 specimens from 132 patients were available, representing the transcriptional state before treatment start, at 12 weeks and after treatment (25 weeks). Pathologic complete response (pCR) in breast and axillary nodes was the primary endpoint. Results: pCR was observed in 15 patients (23%) receiving bevacizumab and chemotherapy and 8 patients (12%) receiving only chemotherapy. In the estrogen receptor-positive patients, 11 of 54 (20%) treated with bevacizumab and chemotherapy achieved pCR, while only 3 of 57 (5%) treated with chemotherapy reached pCR. In patients with estrogen receptor-positive tumors treated with combination therapy, an elevated immune activity was associated with good response. Proliferation was reduced after treatment in both treatment arms and most pronounced in the combination therapy arm, where the reduction in proliferation accelerated during treatment. Transcriptional alterations during therapy were subtype specific, and the effect of adding bevacizumab was most evident for luminal-B tumors. Conclusions: Clinical response and gene expression response differed between patients receiving combination therapy and chemotherapy alone. The results may guide identification of patients likely to benefit from antiangiogenic therapy. Clin Cancer Res; 23(16); 4662-70. ©2017 AACR . (©2017 American Association for Cancer Research.) |
| المشرفين على المادة: | 2S9ZZM9Q9V (Bevacizumab) |
| تواريخ الأحداث: | Date Created: 20170511 Date Completed: 20180430 Latest Revision: 20210103 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1158/1078-0432.CCR-17-0160 |
| PMID: | 28487444 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1557-3265 |
|---|---|
| DOI: | 10.1158/1078-0432.CCR-17-0160 |